Avenacy releases generic Diprivan
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched propofol injectable emulsion, which is a generic of Fresenius Kabi’s Diprivan.
Propofol injectable emulsion is an intravenous general anesthetic and sedation drug indicated for:
- Induction of general anesthesia for patients greater than or equal to 3 years of age;
- Maintenance of general anesthesia for patients greater than or equal to 2 months of age;
- Initiation and maintenance of monitored anesthesia care sedation in adult patients;
- Sedation for adult patients in combination with regional anesthesia; and
- Intensive care unit sedation of intubated, mechanically ventilated adult patients.
[Read more: Avenacy intros generic Reglan]
Avenacy's generic Diprivan is available in 200 mg/20 ml, 500 mg/50 ml and 1,000 mg/100 ml single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, propofol injectable emulsion, will feature the company’s highly differentiated packaging and labeling to support accurate medication selection, Avenacy said.
Propofol injectable emulsion had a market value of approximately $315 million for the 12 months ending in December 2024, per IQVIA.
[Read more: Generic sterile injectables market to reach $196.2B by 2029]